Safety of AAV Factor IX Peripheral Transvenular Gene Delivery to Muscle in Hemophilia B Dogs
Open Access
- 1 July 2010
- journal article
- Published by Elsevier in Molecular Therapy
- Vol. 18 (7) , 1318-1329
Abstract
No abstract availableKeywords
This publication has 56 references indexed in Scilit:
- Immune Responses to AAV in Canine Muscle Monitored by Cellular Assays and Noninvasive ImagingMolecular Therapy, 2010
- Persistent Expression of FLAG-tagged Micro dystrophin in Nonhuman Primates Following Intramuscular and Vascular DeliveryMolecular Therapy, 2010
- Lack of Immunotoxicity After Regional Intravenous (RI) Delivery of rAAV to Nonhuman Primate Skeletal MuscleMolecular Therapy, 2010
- Impact of the Underlying Mutation and the Route of Vector Administration on Immune Responses to Factor IX in Gene Therapy for Hemophilia BMolecular Therapy, 2009
- Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapyProceedings of the National Academy of Sciences, 2009
- Induction of Immune Tolerance to FIX Following Muscular AAV Gene Transfer Is AAV-dose/FIX-level DependentMolecular Therapy, 2009
- Reversal of Blindness in Animal Models of Leber Congenital Amaurosis Using Optimized AAV2-mediated Gene TransferMolecular Therapy, 2008
- Recombinant adeno-associated virus vectors induce functionally impaired transgene product–specific CD8+ T cells in miceJournal of Clinical Investigation, 2007
- Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI)Cancer Immunology, Immunotherapy, 2007
- Major Subsets of Human Dendritic Cells Are Efficiently Transduced by Self-Complementary Adeno-Associated Virus Vectors 1 and 2Journal of Virology, 2007